- In July 2024, Hyloris Pharmaceuticals entered into an agreement with Halex Istar for the licensing and distribution of Maxigesic IV in Brazil, expanding access to this non-opioid pain management solution in one of South America’s largest markets. Maxigesic IV, a combination of paracetamol and ibuprofen, aims to provide enhanced post-operative pain relief while reducing opioid dependency. This collaboration aligns with Hyloris’s strategy to optimize existing drugs for unmet medical needs, with the company expecting revenue growth from royalties and milestone payments
- In January 2023, Hyloris Pharmaceuticals SA partnered with Salus Pharmaceuticals for the exclusive licensing and distribution of Maxigesic IV across nine European countries. This dual-action, non-opioid IV pain treatment, combining paracetamol and ibuprofen, has already been registered in five of these markets, with product launches planned later in 2023. This move supports Hyloris’s vision of repurposing existing drugs and expanding access to innovative, non-opioid pain management solutions
- In April 2022, IOL Chemicals and Pharmaceuticals began commercial production of paracetamol with an installed capacity of 1,800 MTPA, incorporating backward integration of Para Amino Phenol (PAP). This initiative strengthened the company’s production capabilities. In addition, in response to the current market demand, the company is expanding its paracetamol production capacity from 1,800 MTPA to 3,600 MTPA
- In March 2022, Paraveganio became one of the first medicinal products globally to be registered with The Vegan Society's Vegan Trademark. This certified vegan drug contains 500mg of paracetamol, offering a plant-based alternative for pain relief
- In November 2021, Hyloris Pharmaceuticals SA announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for Maxigesic IV, a unique combination of 1000 mg paracetamol and 300 mg ibuprofen for postoperative pain relief. This regulatory milestone allowed the company to broaden the applications of its product and expand its customer base
